BenzingaAugust 6, 2026 at 9:19 AM NY29 days ago

Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story